Advanced Prostate Cancer VL

Shared Decision-Making vs. Physician or Patient-Directed Decisions on Patient Quality of Life and Decision Satisfaction in Metastatic Prostate Cancer - Frank Schumacher

Details
Alicia Morgans is joined by Frank Schumacher to discuss the study results assessing the association of functional outcomes by decision-making approaches in men with metastatic prostate cancer. Dr. Schumacher and colleagues assessed the association of shared decision-making vs. physician- or patient-directed decisions and measurement of patient quality of life, including patient-reported functional...

Clinical Trials in Progress: PSMA-Based Radioligand, 177Lu-PNT2002 For Men With Metastatic Castration-Resistant Prostate Cancer - The SPLASH Study - Neil Fleshner

Details
Charles Ryan is joined by Neil Fleshner to discuss the multi-center, open-label, phase III SPLASH study evaluating the efficacy of 177Lu-PNT2002, a PSMA-based radioligand, for men with progressive metastatic castration-resistant prostate cancer (mCRPC) after androgen receptor axis-targeted (ARAT) therapy which is underway and accruing in many sites around the world. Biographies: Neil Fleshner, MD,...

Clinical Trial Equity in Radionuclide Treatment for Prostate Cancer - Joseph Osborne

Details
Phillip Koo is joined by Joseph Osborne to provide a nuclear radiologist's perspective on the equity in prostate cancer clinical trials. Dr. Osborne focuses his talk on three different aspects of clinical trial equity for prostate cancer: Progress, Evolution, and Goals. He also details the Rad Health Equity Lab, created at Weill Cornell to improve access to radiology and bring awareness to health...

The APCCC 2022 - A Hybrid Meeting April 28 - 30 - Silke Gillessen

Details
Alicia Morgans and Silke Gillessen discuss the upcoming Advanced Prostate Cancer Consensus Conference scheduled as a hybrid meeting taking place on April 28 - 30, 2022 in Lugano, Switzerland. Clinical management of prostate cancer will be discussed including locally advanced high-risk prostate cancer, biochemical recurrence in prostate cancer, and metastatic hormone-sensitive patient treatments, w...

The Risk of Prostate Cancer in Men with Inherited Germline TP53 Variants - Kara Maxwell

Details
In this discussion between Kara Maxwell and Alicia Morgans, Dr Maxwell highlights the role of TP53 in cancer and understanding the Li-Fraumeni syndrome. Inherited germline TP53 pathogenic and likely pathogenic variants (gTP53) cause autosomal dominant multicancer predisposition including Li-Fraumeni syndrome and the work that Drs. Morgans and Maxwell discuss here sought to determine whether gTP53...

From the Stage to the Clinic and Back: Medicine and Burnout - Stuart H. Bloom

Details
Stuart Bloom, MD, a well-known Twin Cities oncologist, joins Charles Ryan, MD to highlight his work on physician burnout including his theatrical play “How to Avoid Burnout in 73 Minutes”. The play represents Dr. Bloom's path to becoming a physician. Dr. Bloom spent the first 30 years of his life as an actor and comedian, the next 31 as a physician. In this conversation, the pair discuss how he co...

Do Our Treatments Drive a New Resistant Mutational Phenotype? - Ana Aparicio

Details
In this UroToday discussion Alicia Morgans and Ana Aparicio, discuss androgen indifferent prostate cancer and how to define those patients. The conversation kicks off with a discussion on the challenges of defining androgen indifferent prostate cancer patients. Dr. Aparicio then goes into a discussion on TP53, RB1, and PTEN alterations, and how they fit into her recent studies. Dr. Morgans and Dr....

A Trial of VERU-100 for the Treatment of Advanced Prostate Cancer – Ronald Tutrone

Details
Alica Morgans is joined by Ronald Tutrone to provide an update on the clinical trial VERU 100. VERU‑100 is a novel, proprietary long-acting gonadotropin-releasing hormone (GnRH) antagonist peptide 3-month subcutaneous depot formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT). Biographies: Ronald Tutrone, MD, FACS, CPI, National Med...

Impact of Age on Castration Rates from The HERO Study – Michael Cookson

Details
Alicia Morgans, MD, MPH, and Michael Cookson, MD, MMHC, FACS, discuss age subgroups in the HERO trial, evaluating differences in castration rates between patients of different ages from the HERO Study. The HERO trial evaluated relugolix compared to standard androgen deprivation therapy with leuprolide. Dr. Cookson discusses how they performed the analysis. The evaluation demonstrated that younger...

HERO Trial: Oral Relugolix for ADT in Advanced Prostate Cancer - Thomas Keane

Details
Tom Keane, MBBCh, FRCSI, FACS, recaps the HERO Phase III Trial comparing the safety and efficacy of relugolix with leuprolide acetate in advanced prostate cancer patients. In this trial, men with advanced prostate cancer who received relugolix achieved rapid, sustained suppression of testosterone levels that were superior to that with leuprolide, with a 54% lower risk of major adverse cardiovascul...
email news signup